According to the report titled ‘Global Gene Therapy Market - Analysis By Vector Type, By Application, By Region, By Country: Market Insights, Covid-19 Impact, Competition and Forecast (2020-2025)’, available with Market Study Report, global gene therapy market size was valued USD 1221.84 million in 2019 and is expected to record a healthy growth rate through 2025.
 

Growing prevalence of various chronic diseases like neurological and cardiovascular disorders, cancer, sickle cell and Alzheimer’s disease is the primary growth driver of global gene therapy market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3056138/
 

Moreover, heavy investments by companies towards incorporating advanced technology are enhancing the growth scope of the industry. Further, increasing collaboration between research institutes and bio-pharma companies advance gene therapy is rendering a positive impact on the overall market dynamics, claims the study.
 

Based on vector type, global gene therapy market is categorized into AAV, lentivirus, AAV, retrovirus & gammaretrovirus, and others. Of these, AAV vectors segment is expected to lead the industry growth in the coming years owing to rising investment in these vectors to accelerate research against strategically selected cell targets.
 

Proceeding further, the report also hosts vast information on application spectrum segmentation hwihc is split into cancer, neurological disorders, cardiovascular diseases, and others.
 

As per the regional analysis, worldwide gene therapy market size spans across North America (United States, Canada), Europe (France, Italy, United Kingdom, Germany), and Asia Pacific (India, China, Japan, South Korea). Among these, North America is touted to gain significant traction during the forecast period, creditable to the presence of major players in the region focusing on expanding their product pipeline.
 

Elaborating on the competitive landscape, top contenders influencing the global gene therapy market dynamics are Sarepta Therapeutics, Inc., Akcea Therapeutics, BlueBird Bio, Inc., AnGes MG, Inc., Orchard Therapeutics plc, MolMed S.p.A., Novartis AG, Spark Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., and Voyager Therapeutics.